Melbourne, Australia, 31 March 2016. Adherium Limited (ASX:ADR), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, has appointed a new Senior Vice President of Business Development and has established an operating entity in the UK to serve the European market. Announcement link here.
Melbourne, Australia, March 23, 2016. Link to announcement here.
16 March 2016: Link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to provide an update on trading since the Company’s Interim Results Statement, released on 8 December 2015. The Directors re-iterate their sales guidance, provided in the Interim Statement, that […]
– Modification of REX to accommodate patients with lower limb loss – Co-operation with Walter Reed National Military Medical Center (WRNMMC), Bethesda, Maryland, US – Potential for “Broad Applicability across the Department of Defense and the Veterans Administration” 11 March 2016: Link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology […]
Effectiveness Submission to the FDA-CVM on Track for 2Q 2016. DUBLIN, Ireland, March 08, 2016 (GLOBE NEWSWIRE) –Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the successful completion of its pilot field study for ranevetmab* (NV-01), the Company’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of […]
Link here. RNS Number : 1434H Rex Bionics PLC · 95% Treatment Success and no adverse events · 95% of volunteers said they would like to use REX on a weekly basis · Next new RAPPER II sites will be the Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK; and Austin Health: Royal Talbot Rehabilitation Centre, Melbourne, Australia 27 November […]
Northridge, CA, USA and Cambridge, United Kingdom, 24 November 2015. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has entered into agreements with specialist wound-care distributors in France and the UK. In France, Medical Z® is a leader in […]
November 23, 2015. Link here. Overview of the symposium: 1, The Animal health industry and opportunities for innovation. 2. An overview of Nexvet: Details of the successful NV-01 pivotal study Next steps for Nexvet’s development programs. PETization and Nexvet’s R&D Finances and corporate structure Partnerships, market opportunities and near-term catalysts Q&A with Nexvet leadership 3. Companion […]
San Diego and Richmond, Va., USA, Ljubljana, Slovenia, and Sydney, Australia, November 19, 2015 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into a Clinical Trial Research Agreement with the University of Adelaide for the purpose of conducting a […]
Primary Endpoint Achieved Conference Call November 16th at 9:00AM ET DUBLIN, Ireland, Nov. 16, 2015 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced positive results from its pivotal safety and efficacy study of NV-01, the Company’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain […]